The associated signaling pathways identified in prostate cancer include adipogenesis, bone metamorphosis, drug resistance drug efflux, epithelial-mesenchymal transition, Th1 and Th2 pathways (Fig 3A), and the upstream regulators viz. Argonaute 2 (AGO2), Double-Stranded RNA-Specific Endoribonuclease (DICER1), Sjogren syndrome antigen B (SSB), neurofibromatosis 2 (NF2), and peroxisome proliferator activated receptor alpha (PPARA) (Fig 3B). This evidence concerns the gene PPARA and prostate carcinoma.